APGE vs. ERAS

Last updated Aug 1, 2026

APGE (Apogee Therapeutics Inc. Common Stock) and ERAS (Erasca, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, APGE returned 84.27%/yr vs 89.91%/yr for ERAS. Their 0.33 correlation means their historical movements had little consistent relationship.

Performance

APGE vs. ERAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Apogee Therapeutics Inc. Common Stock (APGE) and Erasca, Inc. (ERAS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, APGE achieves a 77.65% return, which is significantly lower than ERAS's 387.90% return.

APGE

• 1D: -0.16%
• 1M: 0.89%
• 6M: 104.69%
• YTD: 77.65%
• 1Y: 255.21%
• 3Y*: 84.27%
• 5Y*: —
• 10Y*: —
• ALL TIME*: 82.34%

ERAS

• 1D: -2.84%
• 1M: -1.73%
• 6M: 72.69%
• YTD: 387.90%
• 1Y: 1,205.76%
• 3Y*: 89.91%
• 5Y*: -2.87%
• 10Y*: —
• ALL TIME*: 2.66%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
APGE Apogee Therapeutics Inc. Common Stock	$128.05M	$169.87M	$317.81M
ERAS Erasca, Inc.	$64.00M	$90.42M	$77.82M

APGE vs. ERAS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
APGE Apogee Therapeutics Inc. Common Stock	77.65%	66.62%	62.13%	29.95%
ERAS Erasca, Inc.	387.90%	48.21%	17.84%	-21.40%

Correlation

The correlation between APGE and ERAS is 0.29, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.29
Correlation (3Y) Balances recent behavior with more history.	0.34
Correlation (All Time) Calculated using the full available price history since Jul 14, 2023	0.33

Fundamentals

Market Cap APGE : $8.30B ERAS : $6.30B
EPS APGE : -$3.18 ERAS : -$0.95
PB Ratio APGE : 7.44 ERAS : 14.04
Total Revenue (TTM) APGE : $0.00 ERAS : $0.00
Gross Profit (TTM) APGE : $0.00 ERAS : -$743.00K
EBITDA (TTM) APGE : -$297.75M ERAS : -$279.47M

Return for Risk

APGE vs. ERAS — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

APGE

APGE Risk / Return Rank: 99
APGE Sharpe Ratio Rank: 98
APGE Sortino Ratio Rank: 99
APGE Omega Ratio Rank: 98
APGE Calmar Ratio Rank: 99
APGE Martin Ratio Rank: 99

ERAS

ERAS Risk / Return Rank: 99
ERAS Sharpe Ratio Rank: 100
ERAS Sortino Ratio Rank: 99
ERAS Omega Ratio Rank: 99
ERAS Calmar Ratio Rank: 100
ERAS Martin Ratio Rank: 100

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

APGE vs. ERAS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Apogee Therapeutics Inc. Common Stock (APGE) and Erasca, Inc. (ERAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	APGE	ERAS	Difference
Sharpe ratio: Return per unit of total volatility	3.57	11.46	-7.89
Sortino ratio: Return per unit of downside risk	5.19	5.02	+0.17
Omega ratio: Gain probability vs. loss probability	1.67	1.82	-0.15
Calmar ratio: Return relative to maximum drawdown	10.24	20.11	-9.87
Martin ratio: Return relative to average drawdown	31.57	59.39	-27.82

APGE vs. ERAS - Sharpe Ratio Comparison

The current APGE Sharpe Ratio is 3.57, which is lower than the ERAS Sharpe Ratio of 11.46. The chart below compares the historical Sharpe Ratios of APGE and ERAS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

APGE vs. ERAS - Drawdown Comparison

The maximum APGE drawdown since its inception was -58.75%, smaller than the maximum ERAS drawdown of -95.65%. Use the drawdown chart below to compare losses from any high point for APGE and ERAS.

Drawdown Indicators

	APGE	ERAS	Difference
Max Drawdown Largest peak-to-trough decline	-58.75%	-95.65%	+36.90%
Max Drawdown (1Y) Largest decline over 1 year	-24.63%	-59.46%	+34.83%
Max Drawdown (3Y) Largest decline over 3 years	-58.75%	-67.68%	+8.93%
Max Drawdown (5Y) Largest decline over 5 years	—	-95.65%	—
Current Drawdown Current decline from peak	-0.16%	-25.43%	+25.27%
Average Drawdown Average peak-to-trough decline	-23.26%	-73.43%	+50.17%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.97%	20.10%	-12.13%

Volatility

APGE vs. ERAS - Volatility Comparison

The current volatility for Apogee Therapeutics Inc. Common Stock (APGE) is 0.70%, while Erasca, Inc. (ERAS) has a volatility of 20.49%. This indicates that APGE experiences smaller price fluctuations and is considered to be less risky than ERAS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	APGE	ERAS	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.70%	20.49%	-19.79%
Volatility (6M) Calculated over the trailing 6-month period	52.57%	86.24%	-33.67%
Volatility (1Y) Calculated over the trailing 1-year period	70.76%	104.83%	-34.07%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	71.00%	83.41%	-12.41%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	71.00%	83.32%	-12.32%

Dividends

APGE vs. ERAS - Dividend Comparison

Neither APGE nor ERAS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both APGE and ERAS in my portfolio?

APGE and ERAS have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, APGE or ERAS?

ERAS has higher volatility (20.49%) compared to APGE (0.70%). In terms of maximum drawdown, APGE dropped -58.75% vs ERAS's -95.65%.

Which has better risk-adjusted returns?

ERAS currently has the higher Sharpe Ratio (11.46 vs 3.57), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.